Bifidobacterium bifidum reduced colitis symptoms in a DSS-induced mouse model and modulated microRNA regulation while lowering key inflammatory cytokines. The study reported the strongest recovery in the post-treatment arm, with improvements in colon length and mucosal architecture. A diagnostic review addressed cytomegalovirus testing pitfalls in severe colitis, emphasizing how tissue-invasive CMV disease can be hard to distinguish from incidental reactivation. The authors proposed a pragmatic, unvalidated clinical testing framework using histology, immunohistochemistry, tissue qPCR, and peripheral blood molecular assays. Together, the updates underscore two sides of translational gut science: microbiome-directed interventions are being tested for symptom modulation, while clinicians are being warned that viral detection methods need careful interpretation to guide immunosuppression decisions.